Samsung Bioepis Presents Phase III Data For Eylea Biosimilar
Company Also Releases New Immunogenicity Results On Byooviz Ranibizumab Biosimilar
Samsung Bioepis presented three new studies on two of its blockbuster biosimilars at the American Academy of Ophthalmology 2022 Annual Meeting, including Phase III data for its proposed aflibercept rival to Eylea.
